Analysts Set Expectations for Moderna FY2030 Earnings

Moderna, Inc. (NASDAQ:MRNA) – Brookline Capital Management issued their FY2030 earnings estimates for shares of Moderna in a research report issued to clients and investors on Monday, January 12th. Brookline Capital Management analyst L. Cann expects that the company will post earnings of $21.26 per share for the year. The consensus estimate for Moderna’s current full-year earnings is ($9.61) per share.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($2.15) by $1.64. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $893.29 million. During the same quarter in the prior year, the company posted $0.03 EPS. The company’s quarterly revenue was down 45.4% on a year-over-year basis.

Several other analysts also recently commented on the stock. Morgan Stanley reduced their price target on shares of Moderna from $30.00 to $28.00 and set an “equal weight” rating for the company in a research report on Friday, December 12th. Royal Bank Of Canada restated a “sector perform” rating on shares of Moderna in a research report on Monday. JPMorgan Chase & Co. dropped their price target on Moderna from $26.00 to $25.00 and set an “underweight” rating for the company in a research note on Thursday, October 23rd. Jefferies Financial Group reiterated a “hold” rating on shares of Moderna in a research note on Monday, January 5th. Finally, BMO Capital Markets upgraded shares of Moderna from a “market perform” rating to a “buy” rating in a research note on Monday. Two analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and five have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average price target of $30.36.

Moderna Stock Performance

MRNA opened at $40.91 on Thursday. The stock has a market capitalization of $15.98 billion, a P/E ratio of -5.04 and a beta of 1.17. Moderna has a one year low of $22.28 and a one year high of $45.40. The business’s 50-day simple moving average is $28.97 and its 200-day simple moving average is $28.04.

Insider Buying and Selling at Moderna

In other Moderna news, Director Noubar Afeyan sold 23,853 shares of the firm’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $29.48, for a total value of $703,186.44. Following the sale, the director owned 3,924 shares in the company, valued at approximately $115,679.52. This trade represents a 85.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 10.90% of the stock is currently owned by company insiders.

Institutional Trading of Moderna

Several institutional investors have recently modified their holdings of the company. Rothschild Investment LLC lifted its position in shares of Moderna by 94.1% in the second quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock worth $25,000 after purchasing an additional 446 shares in the last quarter. TD Private Client Wealth LLC increased its position in Moderna by 348.8% during the second quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock worth $26,000 after buying an additional 743 shares during the last quarter. Atlantic Union Bankshares Corp acquired a new stake in shares of Moderna in the second quarter worth about $26,000. Whittier Trust Co. bought a new stake in shares of Moderna during the 2nd quarter worth about $28,000. Finally, MUFG Securities EMEA plc bought a new position in shares of Moderna in the 2nd quarter valued at approximately $28,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.